Cytoreductive nephrectomy

PROCEDURE8 trials

Sponsors

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Niels Fristrup, Mark Stein, SWOG Cancer Research Network, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Conditions

Clear-cell Metastatic Renal Cell CarcinomaCytoreductive NephrectomyImmune Checkpoint InhibitorsKidney CancerMetastatic Clear Cell Renal Cell CarcinomaMetastatic Renal Cell CarcinomaMetastatic Renal Cell Carcinoma ( mRCC)Renal Cell Carcinoma

Phase 2

CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition

Active, not recruitingNCT04322955

Mark SteinKidney Cancer, Renal Cell Carcinoma

Start: 2020-06-22End: 2028-02-01Updated: 2026-06-05

Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

Not yet recruitingNCT06279403

RenJi HospitalClear-cell Metastatic Renal Cell Carcinoma, Cytoreductive Nephrectomy, Immune Checkpoint Inhibitors

Start: 2024-03-01End: 2029-03-01Target: 20Updated: 2024-02-28

Phase 3

Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery

TerminatedNCT02535351

Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoClear-cell Metastatic Renal Cell Carcinoma

Start: 2015-11-30End: 2018-09-28Updated: 2018-11-14

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

RecruitingNCT04510597

SWOG Cancer Research NetworkMetastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8

Start: 2021-03-08End: 2033-07-31Target: 364Updated: 2025-09-09

Unknown Phase

Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial

RecruitingNCT03977571

Niels FristrupKidney Cancer, Renal Cell Carcinoma Metastatic, Synchronous Neoplasm

Start: 2020-07-06End: 2031-12-01Target: 400Updated: 2026-05-04

Primary Metastatic Renal Cell Carcinoma Treated With Immunecheckpoint Inhibitors and Cytoreductive Nephrectomy

Not yet recruitingNCT05941169

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Renal Cell Carcinoma

Start: 2023-08-01End: 2031-04-01Target: 750Updated: 2023-07-12

A prospective study of primary metastatic renal cell carcinoma treated with immunecheckpoint inhibitors and cytoreductive nephrectomy vs primary tumour in place

Active, not recruitingNL-OMON57224

OncologieRenal Cell Carcinoma renal malignancy

Start: 2023-05-01Target: 750Updated: 2025-08-18

Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC

Not yet recruitingNCT07233668

Seoul National University HospitalMetastatic Renal Cell Carcinoma ( mRCC)

Start: 2025-12-01End: 2029-02-01Target: 172Updated: 2025-12-03

Related Papers

Abstract 4141: Multimodal single-cell analysis of systemic immune remodeling induced by cytoreductive nephrectomy combined with immune checkpoint inhibitors in metastatic renal cell carcinoma

Cancer Research2026-04-03

Cytoreductive nephrectomy in the era of immune-checkpoint inhibitors: back to the future?

2026-02-11

PrimerX: A Bayesian Multistage Cohort Embedded Randomised Trial to Evaluate the Role of Deferred Local Therapy of the Primary Tumour in Combination with Immune Checkpoint Inhibitor-based First-line Therapy in Metastatic Renal Cell Carcinoma Patients.

2024-10-142 citations

‘Case of the Month’ from Addenbrooke's Hospital, Cambridge, <scp>UK</scp> : surgery after near complete response to combined immunotherapy and tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma with inferior vena cava tumour thrombus

British Journal of Urology2024-07-16

The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in immune-oncology era (SEVURO-CN): study protocol for a multi-center, prospective, randomized trial.

2024-07-037 citations

Impact of cytoreductive nephrectomy (CN) and treatment (trt) sequence on overall survival (OS) in metastatic non-clear cell renal cell cancer (nccRCC).

Journal of Clinical Oncology2024-06-01

Cytoreductive surgery, systemic treatment, genetic evaluation, and patient perspective in a young adult with metastatic renal cell carcinoma

CA A Cancer Journal for Clinicians2024-04-033 citations

Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial.

2024-02-2425 citations

Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial.

2023-10-1615 citations

PD24-06 ASSESSMENT OF SURGICAL COMPLICATIONS IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA (MCCRCC) RECEIVING PERIOPERATIVE CABOZANTINIB AND NIVOLUMAB ON CYTO-KIK CLINICAL TRIAL

The Journal of Urology2023-03-23

Assessment of surgical complications in patients with metastatic clear cell renal cell carcinoma (mccRCC) receiving perioperative cabozantinib and nivolumab on Cyto-KIK clinical trial.

Journal of Clinical Oncology2023-02-201 citations

Surgical and focal treatment for metastatic renal cell carcinoma: A literature review.

2022-03-269 citations

SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.

Journal of Clinical Oncology2022-02-1614 citations

“PROBE”ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer

Kidney Cancer2021-12-3030 citations

Cyto-KIK: A phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib).

Journal of Clinical Oncology2021-05-204 citations

Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy.

2021-05-0118 citations

Phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib) (Cyto-KIK).

Journal of Clinical Oncology2021-02-203 citations

TARIBO trial: Cytoreductive nephrectomy in metastatic renal cell carcinoma patients treated with targeted agents.

Journal of Clinical Oncology2017-05-20

TARIBO trial: Targeted therapy with or without nephrectomy in metastatic renal cell carcinoma (mRCC)—Liquid biopsy for biomarkers discovery.

Journal of Clinical Oncology2016-05-202 citations